CTNNB1 and glioblastoma: Down-regulation of aldehyde dehydrogenase activity via Wnt/beta-catenin signaling blockade has been recently proposed as a possible means of reducing ALDH-mediated resistance to temozolomide (the chemotherapeutic drug currently used as standard treatment for glioblastoma) [40].